Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder

• Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have initiated a rolling submission of a marketing application to the FDA for zuranolone in major depressive disorder (MDD).

• Zuranolone is an investigational two-week, once-daily oral drug developed for MDD and postpartum depression (PPD).

• The companies have submitted the nonclinical module and plan to submit the remaining components for the MDD filing in 2H of 2022.

• Related: Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study.

• Data from the completed studies of zuranolone in the LANDSCAPE and NEST programs, including data from the ongoing open-label SHORELINE Study in MDD and data from the completed clinical pharmacology studies, will comprise the full submission package.

• The rolling submission process allows completed sections of an application to be submitted to the FDA for review on an ongoing basis.

• Sage and Biogen plan to submit an associated application submission for PPD in the first half of 2023.

• Price Action: SAGE shares are up 0.57% at $31.70, and BIIB stock is down 0.90% at $205.57 during the market session on the last check Monday.

See more from Benzinga

• Biogen Fails To Convince Benefits Of Alzheimer's Drug To European Regulator

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.